- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Top 10 hospitals with inflated prices
Research reported by National Nurses United
National Nurses United’s (NNU) research arm, the Institute for Health and Socio-Economic Policy, conducted research on hospital pricing practices. It found evidence of what the group calls “price gouging” and “racketeering.”
Here are the top 10 hospitals with inflated prices (by total charges as a percent of total costs), according to NNU.
1 Meadowlands Hospital Medical Center, Secaucus, N.J. – 1,192%
2 Paul B. Hall Regional Medical Center, Painsville, K.Y. – 1,186%
3 Orange Park Medical Center, Orange Park, Fla. – 1,139%
4 North Okaloosa Medical Center, Crestview, Fla. – 1,137%
5 Gadsden Regional Medical Center, Gadsden, Ala. – 1,128%
6 Bayonne Medical Center, Bayonne, N.J. – 1,084%
7 Brooksville Regional Hospital, Brooksville, Fla. – 1,083%
8 Heart of Florida Regional Medical Center, Davenport, Fla. – 1,058%
9 Chestnut Hill Hospital, Philadelphia, Pa. – 1,058%
10 Oak Hill Hospital, Spring Hill, Fla. – 1,052%
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
